|
|||||
|
|
The safety of Bosutinib for the treatment of chronic myeloid leukemia |
|
| Authors: | Jee Hyun Kong HJ Khoury Audrey Sunwha Kim Brittany Gray Hill |
| Affiliation: | 1. Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA;2. Division of Hematology, Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA;3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA |
| Abstract: | Introduction: Tyrosine kinase inhibitors (TKIs) are a potentially lifelong treatment for patients with chronic myeloid leukemia (CML). Adverse events (AEs) associated with TKIs are significant impediments in the daily life of patients that can impact compliance, and efficacy. Areas covered: This is a review on safety of bosutinib in the treatment of chronic phase CML. Data is extracted from the latest updates of bosutinib phase I/II and III trials. Expert opinion: Bosutinib is an effective agent against all phases of CML presently approved for the treatment in patients with resistance or intolerance to prior TKI therapy. Bosutinib has a unique toxicity profile characterized by early and transient diarrhea. Otherwise, the AE profile of bosutinib is comparable to other TKIs, with the exception of cardiovascular AEs that are infrequent in bosutinib-treated patients. Similar to other TKIs, the minimum effective dose of bosutinib remains unknown. Better definition of the optimal effective dose may spare, for those patients otherwise benefitting from treatment, unnecessary AEs. |
| Keywords: | Bosutinib chronic myeloid leukemia safety efficacy |